#USA #San Francisco #Hypertrophic Cardiomyopathy #Hengrui Pharma #Braveheart Bio

Positive Phase 2 Results for HRS/BHB-1893

Hengrui Pharma and Braveheart Bio jointly announced the encouraging results from their multi-center Phase 2 study of HRS/BHB-1893, an innovative cardiac myosin inhibitor targeting non-obstructive hypertrophic cardiomyopathy (nHCM). During this study, the investigational medication showed promise in effectively addressing the complexities associated with nHCM, a condition that has few treatment options currently available.

Study Objectives and Design

The Phase 2 trial, which was randomized and double-blind, involved 84 adults diagnosed with symptomatic nHCM. This study aimed to evaluate the safety and tolerability of HRS/BHB-1893 while also measuring its efficacy in improving patients' clinical outcomes and cardiac function.

Key Inclusion Criteria:

• - Patients with left ventricular ejection fraction (LVEF) ≥60%
• - New York Heart Association (NYHA) Class II–III
• - Maximal wall thickness ≥15 mm
• - LVOT-G <30 mmHg
• - NT-proBNP >300 pg/mL

The primary endpoint of the study was to assess the adverse events associated with multiple oral doses of the intervention, while secondary endpoints included various biomarkers and measures of diastolic function, cardiac structure, as well as patient-reported symptoms.

Efficacy and Safety Findings

The treatment with HRS/BHB-1893 resulted in significant improvements in biomarkers indicating cardiac stress and damage. Patients noted enhancements in their symptoms and exercise capacity, with a marked increase in the Kansas City Cardiomyopathy Questionniare Short Form (KCCQ-CSS) scores. Notably, 52% of high-dose participants achieved substantial improvement, signaling a favorable direction in patient health outcomes.

Furthermore, echocardiographic assessments revealed improvements in several important areas, including reductions in left ventricular mass and thickness, signifying a potentially disease-modifying impact. The overall safety profile was promising, with only mild to moderate adverse events reported, which were primarily non-study related.

Clinical Implications

As pointed out by Dr. Anjali Owens, a key member of the clinical advisory board, the ability to isolate the effects of HRS/BHB-1893 in non-obstructive cases provides invaluable insights into the drug's potential. The absence of a left ventricle outflow tract gradient in this patient group highlights the unique advantages of this treatment.

Dr. Sheng Qi from Hengrui Pharma emphasized the importance of this study, stating that achieving improvements across various health metrics in a condition previously deemed difficult to treat indicates that HRS/BHB-1893 could address the underlying pathology effectively.

Next Steps for Development

Following these promising outcomes, both companies aim to further investigate this treatment's effectiveness on a larger scale, preparing for an upcoming global registrational study. The insights from this Phase 2 trial present a beacon of hope for numerous individuals living with nHCM, potentially paving the way for a new standard of care.

Conclusion

This Phase 2 evaluation signifies an important step in developing effective therapeutic options for patients with non-obstructive hypertrophic cardiomyopathy. With ongoing research and a commitment to advancing treatment, Hengrui Pharma and Braveheart Bio are poised to make significant contributions to cardiovascular medicine.